07.08.26 -- OPCU: Capabilities For Scaling Advanced Therapeutics

Scale cell therapies efficiently by adopting automated, closed systems and advanced analytical testing to reduce contamination risks, ensure regulatory compliance, and secure patient supply.

Accelerate cell therapy timelines from the start by integrating donor sourcing, GMP manufacturing, and cryopreservation in a unified workflow that reduces logistical risks.

Boost clinical readiness with phase-appropriate systems and standardized tech transfer playbooks. Align process development with late-stage manufacturing for predictable production.

Discover a practical roadmap for scaling cell therapies by unifying facility design, process standardization, and digital execution to reduce variability and accelerate commercial production.

Expedite biotherapeutic development with integrated workflows. Learn how stable pools and advanced vectors decouple material generation from clone selection, de-risking clinical scale-up.

Assimilate how an integrated approach to transient expression, cell line development, and manufacturing can accelerate biologics development from gene to IND.

Next-gen CMC uses high-performing cell lines to accelerate timelines, improve consistency, and scale efficiently, leveraging gains in stability, pool quality, and process intensification.

Explore how integrated cell line development and early-stage capabilities enable faster timelines while building a strong foundation for clinical and commercial success.

Targeted integration improves titer, stability, and consistency in cell line development, accelerating timelines, reducing risk, and enabling scalable, data-driven CMC for complex biologics.